Cancer is an insidious enemy, and its kaleidoscope of genetic mutations often makes precision therapy so elusive. A group of Chinese scientists sought to cover all options in his one map of potential drugs for head and neck squamous cell carcinoma (HNSCC).
HNSCC is often not diagnosed until it is at a more advanced stage, and currently most new drug candidates targeting mutated proteins and enzymes have shown limited success in early studies.
A study published Thursday in the journal Science Translational Medicine reported a large repository of patient-derived cells that could help rapidly translate research into therapies and biomarkers for this cancer.
A research group led by Zhang Zhiyuan and Sun Shuyang at Shanghai Jiao Tong University has constructed a repository of 56 cell lines derived from HNSCC patient samples. A genetic trait, according to researchers.
Using this extensive resource, the team will search both clinical and preclinical-stage FDA-approved drugs and drugs for promising drug candidates that could neutralize cancer cells, according to Xinhua’s website. We screened over 2,200 compounds containing compounds.
Based on this model, the researchers identified 129 promising drugs and experimental compounds that may be suitable for repurposing HNSCC, and studies show that two conventional drugs, fedratinib and mitoxan, We confirmed that thoron may be used for two types of HNSCC, respectively. .
The experiment also revealed that a gene called ITGB1 can act as a biomarker and predict a patient’s response to the chemotherapy drug docetaxel.